Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mega GenomicsHKSE:06667 -0.28%71 PB Ratio is 2.27 as of Sep. 06, 2026, which is 20% below its 10-year median of 2.83. GuruFocus rates HKSE:06667 with a GF Score™ of 71/100 and a GF Value™ of HK$16.92 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 190 Medical Diagnostics & Research companies, Mega Genomics ranks worse than 55.26% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-09-06), Mega Genomics's share price is HK$7.075. Mega Genomics's Book Value per Share for the quarter that ended in Dec. 2025 was HK$3.12. Hence, Mega Genomics's PB Ratio of today is 2.27.
Good Sign:
Mega Genomics Ltd stock PB Ratio (=2.27) is close to 5-year low of 2.15.
The historical rank and industry rank for Mega Genomics's PB Ratio or its related term are showing as below:
HKSE:06667'
s PB Ratio Range Over the Past 10 Years
Min: 2.15 Med: 2.83 Max: 5.07
Current: 2.27
During the past 7 years, Mega Genomics's highest PB Ratio was 5.07. The lowest was 2.15. And the median was 2.83.
HKSE:06667's PB Ratio is ranked worse than 55.26% of 190
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.05
vs HKSE:06667: 2.27
During the past 12 months, Mega Genomics's average Book Value Per Share Growth Rate was 6.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 1.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 17.10% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Mega Genomics was 50.30% per year. The lowest was -7.30% per year. And the median was 1.40% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Mega Genomics PB Ratio Related Terms
Mega Genomics PB Ratio Historical Data
* Premium members only.
The historical data trend for Mega Genomics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Mega Genomics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mega Genomics PB Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Mega Genomics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Mega Genomics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Mega Genomics's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Mega Genomics (HKSE:06667) has a PB Ratio of 2.27 as of Sep. 06, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Mega Genomics and its competitors. This is 20% below median its historical median of 2.83. Over the past decade, Mega Genomics' PB Ratio has ranged from 2.15 to 5.07. According to the industry distribution chart, Mega Genomics ranks #105 out of 190 companies in the Medical Diagnostics & Research industry, placing it in the top 55.3%.
Is Mega Genomics' PB Ratio too high?
Mega Genomics' current PB Ratio of 2.27 is 20% below median its 10-year median of 2.83. Over the past 10 years, this metric has ranged from a low of 2.15 to a high of 5.07. The Medical Diagnostics & Research industry median PB Ratio is 2.05. Mega Genomics' value of 2.27 is 10.7% above this industry median. Based on the distribution chart, Mega Genomics ranks #105 out of 190 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Mega Genomics has a GF Score™ of 71/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mega Genomics' PB Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Mega Genomics ranks #105 out of 190 companies for PB Ratio. This places Mega Genomics in the lower half of its industry. The industry median PB Ratio is 2.05. Mega Genomics' value of 2.27 is 10.7% above this benchmark. Historically, Mega Genomics' own PB Ratio has ranged from 2.15 to 5.07 over the past decade. While the company's 10-year median is 2.83 vs. the industry median of 2.05, Mega Genomics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Diagnostics & Research company?
The median PB Ratio among Medical Diagnostics & Research companies is 2.05, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mega Genomics's current PB Ratio of 2.27 is 10.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Mega Genomics and its competitors. For the Medical Diagnostics & Research industry, the median PB Ratio is 2.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mega Genomics's current PB Ratio is 2.27, which is 20% below median its own 10-year median of 2.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mega Genomics stock overvalued right now?
Based on GuruFocus' analysis, Mega Genomics (HKSE:06667) is currently considered Possible Value Trap. The stock's GF Value™ is HK$16.92, compared to a current price of HK$7.08 — trading 58.2% below its estimated fair value. The current PB Ratio is 2.27, which is 20% below median its 10-year median of 2.83 and 10.7% above the Medical Diagnostics & Research industry median of 2.05. Mega Genomics' overall GF Score™ is 71/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Mega Genomics (HKSE:06667), the current PB Ratio is 2.27 as of Sep. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mega Genomics (HKSE:06667) Overvalued in 2026?
Based on GuruFocus' analysis, Mega Genomics stock appears to be undervalued.
The current stock price of HK$7.08 is trading 58.2% below its estimated GF Value™ of HK$16.92.
GuruFocus considers Mega Genomics to be Possible Value Trap.
Key valuation signals for HKSE:06667:
PB Ratio: 2.27 (20% below median its 10-year median of 2.83)
GF Value™: HK$16.92 vs. price of HK$7.08 (58.2% below fair value)
Industry Position: 10.7% above the Medical Diagnostics & Research median (#105 of 190)
No single metric tells the full story. See the HKSE:06667 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mega Genomics Ltd is a genetic testing platform company in China with a focus on consumer genetic testing and cancer screening services, ancillary services, and related products in the PRC. The company has launched dozens of testing services, covering a wide range of fields such as nutrition and metabolism, cancer risk assessment, chronic disease susceptibility, cancer screening, and infectious disease diagnosis, to meet consumers' growing preventive medical needs. It generates a majority of its revenue from consumer genetic testing services.
71GF Score
Get the complete analysis for HKSE:06667
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06667 has been successfully added to your 
